A Germline Mutation in SRRM2, a Splicing Factor Gene, is Implicated in Papillary Thyroid Carcinoma Predisposition

Overview

Journal Sci Rep

Specialty Science

Date 2015 Jul 3

PMID 26135620

Citations 50

Authors

Jerneja Tomsic

Huiling He

Keiko Akagi

Sandya Liyanarachchi

Qun Pan

Blake Bertani

Rebecca Nagy

David E Symer

Benjamin J Blencowe

Albert de la Chapelle

Affiliations

Soon will be listed here.

Abstract

Papillary thyroid carcinoma (PTC) displays strong but so far largely uncharacterized heritability. Here we studied genetic predisposition in a family with six affected individuals. We genotyped all available family members and conducted whole exome sequencing of blood DNA from two affected individuals. Haplotype analysis and other genetic criteria narrowed our list of candidates to a germline variant in the serine/arginine repetitive matrix 2 gene (SRRM2). This heterozygous variant, c.1037C > T (Ser346Phe or S346F; rs149019598) cosegregated with PTC in the family. It was not found in 138 other PTC families. It was found in 7/1,170 sporadic PTC cases and in 0/1,404 controls (p = 0.004). The encoded protein SRRM2 (also called SRm300) is part of the RNA splicing machinery. To evaluate the possibility that the S346F missense mutation affects alternative splicing, we compared RNA-Seq data in leukocytes from three mutation carriers and three controls. Significant differences in alternative splicing were identified for 1,642 exons, of which a subset of 7 exons was verified experimentally. The results confirmed a higher ratio of inclusion of exons in mutation carriers. These data suggest that the S346F mutation in SRRM2 predisposes to PTC by affecting alternative splicing of unidentified downstream target genes.

Citing Articles

High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms.

Li S, Huang X, Zheng S, Zhang W, Liu F, Cao Q BMC Cancer. 2024; 24(1):580.

PMID: 38735973 PMC: 11088775. DOI: 10.1186/s12885-024-12346-y.

SRRM2 splicing factor modulates cell fate in early development.

Carvalho S, Zea-Redondo L, Tang T, Stachel-Braum P, Miller D, Caldas P Biol Open. 2024; 13(4).

PMID: 38656788 PMC: 11070786. DOI: 10.1242/bio.060415.

Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.

Jiang Y, Xia Y, Han Z, Hu Y, Huang T Front Oncol. 2024; 14:1286426.

PMID: 38571492 PMC: 10987779. DOI: 10.3389/fonc.2024.1286426.

SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection.

Guo J, Zhang Z, Wang H, Li Q, Fan M, Zhang W Clin Exp Med. 2024; 24(1):28.

PMID: 38289482 PMC: 10827842. DOI: 10.1007/s10238-023-01272-1.

Familial and genetic association with neurodevelopmental disorders caused by a heterozygous variant in the gene.

Zhang T, Xu L, Zhu H, Ying Y, Ding J, Ding H Front Endocrinol (Lausanne). 2023; 14:1240168.

PMID: 37621647 PMC: 10445754. DOI: 10.3389/fendo.2023.1240168.

References

Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K . Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2013; 106(1):djt338. PMC: 3906987. DOI: 10.1093/jnci/djt338. View

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Saltzman A, Pan Q, Blencowe B . Regulation of alternative splicing by the core spliceosomal machinery. Genes Dev. 2011; 25(4):373-84. PMC: 3042160. DOI: 10.1101/gad.2004811. View

Jendrzejewski J, He H, Radomska H, Li W, Tomsic J, Liyanarachchi S . The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A. 2012; 109(22):8646-51. PMC: 3365219. DOI: 10.1073/pnas.1205654109. View

Yu G, Li J, Branovan D, McCormick S, Schantz S . Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid. 2010; 20(5):465-73. DOI: 10.1089/thy.2008.0281. View

Bonora E, Tallini G, Romeo G . Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. J Oncol. 2010; 2010:385206. PMC: 2902056. DOI: 10.1155/2010/385206. View

Zheng Z, Geng J, Yao R, Li C, Ying D, Shen Y . Molecular defects identified by whole exome sequencing in a child with Fanconi anemia. Gene. 2013; 530(2):295-300. DOI: 10.1016/j.gene.2013.08.031. View

Risch N . The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev. 2001; 10(7):733-41. View

Parkhomchuk D, Borodina T, Amstislavskiy V, Banaru M, Hallen L, Krobitsch S . Transcriptome analysis by strand-specific sequencing of complementary DNA. Nucleic Acids Res. 2009; 37(18):e123. PMC: 2764448. DOI: 10.1093/nar/gkp596. View

10.

Lupski J, Belmont J, Boerwinkle E, Gibbs R . Clan genomics and the complex architecture of human disease. Cell. 2011; 147(1):32-43. PMC: 3656718. DOI: 10.1016/j.cell.2011.09.008. View

11.

Khanna M, van Bakel H, Tang X, Calarco J, Babak T, Guo G . A systematic characterization of Cwc21, the yeast ortholog of the human spliceosomal protein SRm300. RNA. 2009; 15(12):2174-85. PMC: 2779666. DOI: 10.1261/rna.1790509. View

12.

Blencowe B, Bauren G, Eldridge A, Issner R, Nickerson J, Rosonina E . The SRm160/300 splicing coactivator subunits. RNA. 2000; 6(1):111-20. PMC: 1369899. DOI: 10.1017/s1355838200991982. View

13.

Kutyavin I, Milesi D, Belousov Y, Podyminogin M, Vorobiev A, Gorn V . A novel endonuclease IV post-PCR genotyping system. Nucleic Acids Res. 2006; 34(19):e128. PMC: 1636472. DOI: 10.1093/nar/gkl679. View

14.

Blencowe B, Issner R, Nickerson J, Sharp P . A coactivator of pre-mRNA splicing. Genes Dev. 1998; 12(7):996-1009. PMC: 316672. DOI: 10.1101/gad.12.7.996. View

15.

Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson J, Tavtigian S . A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996; 13(1):117-9. DOI: 10.1038/ng0596-117. View

16.

Malchoff C, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V . Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000; 85(5):1758-64. DOI: 10.1210/jcem.85.5.6557. View

17.

Ngan E, Lang B, Liu T, Shum C, So M, Lau D . A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J Natl Cancer Inst. 2009; 101(3):162-75. DOI: 10.1093/jnci/djn471. View

18.

Visconte V, Makishima H, Maciejewski J, Tiu R . Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 2012; 26(12):2447-54. PMC: 3645466. DOI: 10.1038/leu.2012.130. View

19.

Bessonov S, Anokhina M, Will C, Urlaub H, Luhrmann R . Isolation of an active step I spliceosome and composition of its RNP core. Nature. 2008; 452(7189):846-50. DOI: 10.1038/nature06842. View

20.

Yu T, Chahrour M, Coulter M, Jiralerspong S, Okamura-Ikeda K, Ataman B . Using whole-exome sequencing to identify inherited causes of autism. Neuron. 2013; 77(2):259-73. PMC: 3694430. DOI: 10.1016/j.neuron.2012.11.002. View